详文均见于”最近进展”（除非另有说明）; 同一文章可能见于本节内不同分类
Full articles can be found under “Recent Progress” unless specified; same reports may be classified under different categories in this section
乳腺癌 Breast cancer
2020/12/19: Amcenestrant对绝经后雌激素受体阳性的乳腺癌妇女显示抗肿瘤活性 (12/19/2020)
2020/11/28: LUM成像系统用于乳腺癌手术 LUM imaging system used in breast cancer surgery
2020/10/31: 手术前内分泌治疗对保乳手术率的影响 Neoadjuvant endocrine therapy on the rates of breast-conversing surgery
2020/10/24: Sacituzumab govitecan对激素受体阳性/HER-2阴性的乳腺癌有效Sacituzumab govitecan appears to be active for advanced stage of ER-positive/HER-2-negative breast cancer
2020/10/17: 延迟手术前化疗会对乳腺癌患者生存产生影响 Delayed neoadjuvant chemotherapy could impact overall survival in breast cancer patients
2020/10/10: 辅助性Abemaciclib加内分泌治疗用于高复发率的早期乳腺癌 Adjuvant abemaciclib plus standard endocrine therapy in early breast cancer patients at high risk of recurrence
2020/9/26: 曲妥珠单抗在早期乳腺癌中治疗持续时间: 荟萃分析 Meta-analysis of duration of transtuzumab in early breast cancer
2020/8/29: 最近进展–>口服Tesetaxel用于转移性乳腺癌患者 Oral Tesetaxel in metastatic breast cancer
2020/8/1: AKT抑制剂ipatasertib治疗晚期三阴性乳腺癌的生存益处 Survival benefit of an AKT inhibitor in triple-negative breast cancer
2020/7/26: 口服选择性雌激素受体降解剂的活性 Oral selective estrogen receptor degrader has activity
2020/7/18: 预测三阴性乳腺癌复发的血液生物标志物 Blood biomarkers in predicting recurrence after neoadjuvant therapy for triple-negative breast cancer
2020/7/5: 手术治疗乳腺癌对转移性患者并不提高总生存率 Surgery did not increase overall survival for de novo metastatic breast cancer patient
2020/5/30: 术前后使用pembrolizumab有益于早期三阴性乳腺癌Neoadjuvant and adjuvant pembrolizumab benefited early stage triple-negative breast cancer
2020/5/17: Sacituzumab govitecan-hziy用于转移性三阴性乳腺癌 Sacituzumab govitecan-hziy for triple-negative breast cancer
2020/5/10: 术前Durvalumab / Olaparib用于HER2阴性乳腺癌 Durvalumab/Olaparib combination with chemotherapy in preoperative HER-2-negative breast cancer
2020/4/12: 编辑RNA可提供对（小鼠）三阴性乳腺癌精确治疗Editing RNA provides accurate target in triple-negative breast cancer in mouse model
2020/3/29: Ribociclib/来曲唑在雌激素受体阳性/HER2-阴乳腺癌中与术前化疗效果相当 Ribociclib/Letrozole vs neoadjuvant chemotherapy in post-menopausal ER-positive/HER2-negative breast cancer
2020/3/28: 乳腺癌化疗期间服用抗氧化剂和某些补品可能弊大于利 Taking antioxidants and some supplements during chemotherapy may be harmful
2020/3/21: 绝经后妇女单独使用雌激素有保护作用(?)，但雌激素加孕激素有害 Estrogen alone protective to postmenopausal women (?) while estrogen plus progesterone harmful
2020/3/7: AKT抑制剂Capivasertib和氟维司群用于对芳香化酶抑制剂耐药的晚期雌激素受体阳性乳腺癌 AKT inhibitor and fulvestrant used in advanced ER-positive breast cancer refractory to aromatase inhibitor
2020/1/19: 新的纳米颗粒疗法在治疗三阴性乳腺癌方面比 Protein Bound Paclitaxel（Abraxane）更有效 New nanoparticle drug more effective than standard therapy for triple-negative breast cancer
肺癌 Lung cancer
2020/12/6: Amivantamab-lazertinib组合可安全治疗EGFR突变的非小细胞肺癌 Amivantamab-lazertinib combination can be safely used in EGFR-mutated NCSLC
2020/9/27: Sotorasib治疗具有KRASG12C基因突变的肿癌 Sotorasib targeting cancers harboring KRASG12C mutation
2020/9/19: 抑制SHP2可望克服肺癌的多种耐药机制 SHP2 inhibitor overcomes resistance mechanisms towards osimertinib
2020/9/13: 下一代ALK抑制剂Ensartinib提高ALK阳性的非小细胞肺癌的无进展生存期 Next-generation ALK-inhibitor Ensartinib benefited ALK-positive non-small cell lung cancer in PFS
2020/9/6: 见”实体肿瘤->肺->非小细胞->无法切除或转移”: 无驱动程序改变的IV期非小细胞肺癌治疗: ASCO和OH（Ontario Health）联合指南 Please see “Solid Tumor–>Lung–>Non-small cell –> Unresectable or metastatic”:Therapy for stage IV non-small cell lung cancer without driver alterations: Joint guideline from ASCO and OH
2020/8/30: RET抑制剂selpercatinib在RET基因融合的肺癌患者中的效果Efficacy of RET inhibitor selpercatinib in RET fusion-positive lung cancer patients
2020/8/23: Capmatinib用于MET-阳性的非小细胞肺癌 Capmatinib used in MET-positive NSCLC
2020/8/16: XMT-1536治疗高度浆液性卵巢癌和非小细胞肺腺癌 XMT-1536 for high-grade serous ovarian cancer and NSCLC
2020/8/2: 第一线Pembrolizumab加标准化疗可改善广泛期小细胞肺癌的无进展生存率 First line pembrolizumab plus standard chemotherapy improves progression-free survival in small cell lung cancer
2020/6/20: FDA批准了Lurbinectedin治疗进展的转移性小细胞肺癌FDA granted accelerated approval to Lurbinectedin for metastatic small cell lung cancer
2020/6/14: 一种血液中循环的巨噬细胞融合细胞可判断非小细胞肺癌患者预后 Circulating giant tumor-macrophage fusion cells are independent prognostic factor of non-small cell lung cancer
2020/5/23: Atezolizumab被FDA批准用于一线治疗某些转移性非小细胞肺癌患者 FDA has just approved Atezolizumab for first-line therapy on certain non-small cell lung cancer patients
2020/3/14: 白血病药物有望治疗耐药性肺癌 Leukemia drugs offer hope for drug-resistant lung cancer
2020/2/23: 奥西替尼和Savolitinib组合在EGFR阳性/MET扩增的晚期非小细胞肺癌有抗肿瘤活性 Osimertinib and savolitinib combination has potential in EGFR-mutated and MET amplified advanced NSCLC
2020/2/2: HIV蛋白酶抑制剂nelfinavir联合放化疗治疗不可切除的IIIA / IIIB期非小细胞肺癌 Combination of HIV protease inhibitor nelfinavir and chemo-radiation in unresectable ST IIIA/IIIB NSCLC
结直肠癌 Colorectal cancer
2020/10/25: 第一线单药派姆单抗改善了转移性结直肠癌患者的无进展生存期和生活质量First line pembrolizumab improvise life quality compared with standard chemotherapy in metastatic colorectal cancer
2020/9/27: Sotorasib治疗具有KRASG12C基因突变的肿癌 Sotorasib targeting cancers harboring KRASG12C mutation
2020/5/24: Trifluridine/Tipiracil联合贝伐单抗用于化疗难治性转移性大肠癌 Trifluridine/Tipiracil in combination with bevacizumab for chemo-refractory colorectal cancer
2020/5/9: Onvansertib在KRAS突变型转移性大肠癌中有前景Onvansertib plus FOLFIRI/Bevacizumab appeared promising in metastatic colorectal cancer with KRAS mutation
2020/2/9: 西妥昔单抗对肝转移可切除的结直肠癌生存期不利Cetuximab may shorten overall survival in resectable colorectal liver metastases
胰腺癌
2020/8/22: 一种使胰腺癌对免疫疗法有效应的药物 (8/22/2020)Development of a drug that makes pancreatic cancer responsive to immunotherapy
2020/3/14: 具有或不具有Veliparib的化疗在BRCA/PALB2 +胰腺癌中的作用 Gemcitabine/cisplatin with or without veliparib highly active in pancreatic adenocarcinoma patients with known germline BRCA/ PALB2 mutation
2020/3/1: 新的药物组合和顺序对治疗胰腺癌有希望 New drug combination and sequencing shows promise in pancreatic cancer treatment
2020/1/12: 白介素-1β可以关闭胰腺癌细胞的抗癌免疫反应 Interleukin-1β can turn off the anti-cancer immune response towards pancreatic cancer
胃癌 Gastric cancer
2020/11/14: Nivolumab/化疗联合治疗可延长胃/食管/胃食管连接癌的生存期 Nivolumab plus chemotherapy may prolong survival in gastric/esophageal/GE-junctional carcinoma
2020/2/22: Trifluridine/Tipiracil对转移性胃癌的疗效与先前的胃切除术无关Efficacy of Trifluridine/Tipiracil in metastatic gastric cancer with or without gastrectomy
肝细胞癌 Hepatocellular carcinoma
2020/11/22: FDA授予SRF388快速通道称号用于治疗肝细胞癌 (11/22/2020) FDA granted fast track designation to SRF338 to treat refractory hepatocellular carcinoma
2020/2/1: Atezolizumab 加上贝伐单抗对无法切除的肝细胞癌有希望Atezolizumab plus Bevacizumab offers hope for unresectable hepatocellular carcinoma
胆管癌 Biliary tract cancer
2020/10/4: 最近进展–>Ivosidenib可延长胆管癌和IDH1突变患者无进展生存时间 Ivosidenib provided prolonged progression-free survival in cholangiocarcinoma with IDH1 mutation
2020/1/25: 治疗晚期胆管癌药物infigratinib获得FDA快速治疗指定
Infigratinib received fast track and orphan drug designation for first line treatment of advanced cholangiocarcinoma
胃肠道间质瘤 GIST
2020/1/5: 关键的研究评估了第四线治疗晚期胃肠道间质瘤（GIST）的TKI Pivotal study of a TKI for fourth line therapy for GIST
浆液性子宫癌 Uterine serous carcinoma
2020/4/26: 新的靶向药物治疗浆液性子宫癌 New drug targeting uterine serous carcinoma
卵巢癌 Ovarian cancer
2020/11/7: 最近进展–>ASCO 关于PARP抑制剂对卵巢癌的治疗指南 ASCO guideline about management of ovarian cancer using PARP Inhibitors
2020/10/3: 最近进展–>溶瘤痘苗病毒（Olvi-Vec）为主的免疫化疗治疗铂类耐药/治性卵巢癌病人Olvi-Vec-primed immunochemotherapy treating platinum-resistant/refractory ovarian cancer
2020/9/20: 亲脂性他汀类降脂药可减少卵巢癌患者的死亡率 Use of lipophilic statins associated with reduced ovarian cancer mortality
2020/9/5: Berzosertib加上吉西他滨治疗耐铂类高度浆液性卵巢癌 Berzosertib plus gemcitabine effective in treating platinum-resistant high-grade serous ovarian cancer
2020/8/16: XMT-1536治疗高度浆液性卵巢癌和非小细胞肺腺癌 XMT-1536 for high-grade serous ovarian cancer and NSCLC
2020/6/27: 针对癌细胞生长所需蛋白质的药物berzosertib与化疗结合，对卵巢癌有益 Chemotherapy in combination with berzosertib, which targets proteins required for cancer cell growth, benefited ovarian cancer
2020/6/21: Niraparib加上贝伐单抗可改善复发性卵巢癌的临床疗效 Niraparib and bevacizumab combination improved clinical outcome among recurrent ovarian cancer
2020/6/13: VB-111（ofranergene obadenovec）用于耐受铂类的卵巢癌VB-111 used in platinum-refractory ovarian cancer
2020/6/6: 二次减细胞手术延长对铂敏感的复发性卵巢癌女性的生存Secondary cytoreductive surgery may extend overall survival among platinum-sensitive ovarian cancer patients
2020/5/16: KRAS突变可能预测某些卵巢癌中MEK抑制剂的益处 KRAS mutation status may predict benefit of MEK inhibitor in certain ovarian cancer
2020/1/11: 尼武单抗和贝伐联合治疗对复发性卵巢癌安全有效 Combination of Nivolumab and bevacizumab is safe and effective for relapsed ovarian cancer
宫颈癌 Cervical cancer
2020/12/27: 针对宫颈癌的图像引导强度调制放射治疗肠道副作用更少 Image-guided IMRT reduces GI toxicity in cervical cancer
2020/12/5: Tisotumab vedotin治疗复发或转移性宫颈癌有临床活性 Tisotumab vedotin demonstrated clinical activity against recurrent/refractory cervical cancer
前列腺癌 Prostate cancer
2020/8/8: Darolutamide提高非转移性去势抵抗性前列腺癌的总生存率Darolutamide improves overall survival in non-metastatic castration-resistant prostate cancer
2020/5/2: 卡博替尼加Atezolizumab对转移性去势抵抗性前列腺癌有活性 Cabozantinib and Atezolizumab were active in metastatic castration-resistant prostate
2020/3/8: 抗抑郁药可能是复发性前列腺癌的新疗法 Anti-depression drug may be able to treat recurrent prostate cancer
肾癌 Kidney cancer
2020/2/29: 治疗透明细胞肾癌靶向癌症驱动分子的药物 A new drug targeting cancer driver molecule in clear cell renal cell cancer
尿路上皮癌 Urothelial cell carcinoma
2020/12/13: Enfortumab Vedotin在膀胱癌中具有生存益处 Enfortumab Vedotin showed survival benefit in bladder cancer
2020/2/16: Sitravatinib加上尼诺单抗对晚期尿路上皮癌有活性Sitravatinib in combination with Nivolumab has activity in locally advanced or metastatic urothelial carcinoma
头颈部癌 Head and Neck cancer
2020/12/12: 针对CD-47的ALX148开始临床II期头颈癌临床试验Phase II clinical research to study ALX148 targeting CD-47 in advanced head-and neck cancer
2020/4/18: 免疫调节剂可增强晚期头颈癌的免疫治疗反应 Immune-restorative agents may boost response to immunotherapy in head-neck cancer
2020/3/22: Tipifarnib可在HRAS突变型头颈部鳞状细胞癌中获得完全疾病控制 Tipifarnib had complete control of HRAS-mutant head and neck squamous cell carcinoma
脑瘤 Brain cancer
2020/7/4: 血液检查诊断脑肿瘤 Blood test to diagnose and classify brain cancer
黑色素瘤 Melanoma
2020/4/25: 术前T-VEC用于高危黑色素瘤 Adjuvant T-VEC in high-risk melanoma
B细胞恶性肿瘤 B-cell malignancies
2020/11/1: 针对CD19 的同种异体CTX11在复发/难治性恶性B细胞恶性肿瘤的1期临床试验结果 Results of phase I clinical trial using allogeneic CTX11 in recurrent/relapsed CD19-positive B-cell malignancy
2020/6/28: FDA批准Selinexor用于复发性或难治性弥漫性大B细胞淋巴瘤FDA has approved Selinexor for relapsed or refractory diffuse large B-cell lymphoma
2020/5/31: 第二代双特异性抗体在难治性淋巴瘤中显示出活性 Second-generation bispecific antibodies shows promising activity in refractory lymphoma
2020/5/3: 现成的CAR T细胞对非霍奇金淋巴瘤安全和有效 Off-the-shelf CA-T product appears safe and effective for non-Hodgkin lymphoma
2020/4/4: 针对B细胞恶性肿瘤的多抗原靶向CAR NK细胞治疗 Novel CAR NK cell therapy targeting multiantigen in B-cell malignancies
多发性骨髓瘤/轻链淀粉样变性 Multiple myeloma/AL amyloidosis
2020/11/8: Ixazomib作为多发性骨髓瘤未进行自体干细胞移植的维持治疗延长了无进展生存期 Ixazomib as maintenance therapy prolonged progression-free survival in newly-diagnosed multiple myeloma not undergoing autologous stem cell transplantation
2020/8/9: Belantamab mafodotin治疗复发/难治性多发性骨髓瘤 Belantamab mafodotin for relapsed or refractory myeloma
2020/6/6: Selinexor / Bortezomib /地塞米松三联体改善多发性骨髓瘤的无进展生存期 Selinexor added to Bortezomib/dexamethasone improved PFS in recurrent multiple myeloma
2020/4/11: 最近进展–>系统性轻链淀粉样变性和心脏受累患者的双重单克隆抗体治疗Dual monoclonal antibody for systemic AL amyloidosis with cardiac involvement
2020/2/15: 下一代针对BCMA的 CAR T细胞疗法治疗多发性骨髓瘤 Next generation BCMA-targeted CAR-T cell therapy for multiple myeloma
骨髓增生异常综合症 Myelodysplastic syndrome
2020/10/18: 最近进展–>抗CD47抗体Magrolimab有望用于骨髓增生异常综合征和急性粒细胞性白血病的治疗 Anit-CD47 monoclonal antibody Magrolimab is hopeful in MDS and AML
2020/8/15: Pevonedistat加上azacitidine可能会增加骨髓增生异常综合症（MDS）/急性粒细胞白血病（AML）的存活率 Pevonedistat plus azacytidine may have survival benefit in MDS and AML patients
2020/7/12 Cedazuridine 被FDA批准与地西他滨合用于成年骨髓增生异常综合症（MDS） FDA has approved cedazuridine and decitabine in adult MDS patients
2020/2/8: APR-246和Azacitidine对有TP53突变的骨髓增生异常综合症的安全性和有效性 Safety and efficacy of combination therapy of APR-246 and azacytidine towards MDS with TP53 mutation
肿瘤生物学和治疗/诊断新进展 Tumor biology &New treatment/diagnosis strategy
2020/12/26: 双特异性分子MGD019在经过多线治疗的实体瘤中有潜在的用途 Dual specific agent has potential activity against solid tumors after multiple-lines of therapy
2020/12/20: 晚期癌症异常良好治疗响应者的可能关键 (12/20/2020)Study on exceptional responders in advanced cancer reveals possible key elements
2020/11/28: LUM成像系统用于乳腺癌手术 LUM imaging system used in breast cancer surgery
2020/11/21: 新的DNA修复抑制剂可增加脑转移对放射的敏感性 A new DNA repair inhibitor may sensitize brain metastases to radiation
2020/10/11: 靶向ILT4的MK-4830抗体有希望的I期临床试验结果 MK-4830 monoclonal antibody targeting ILT4 shows promising results in phase I clinical trial
2020/10/3: 最近进展–>溶瘤痘苗病毒（Olvi-Vec）为主的免疫化疗治疗铂类耐药/治性卵巢癌病人Olvi-Vec-primed immunochemotherapy treating platinum-resistant/refractory ovarian cancer
2020/9/27: Sotorasib治疗具有KRASG12C基因突变的肿癌 Sotorasib targeting cancers harboring KRASG12C mutation
2020/7/19: RAF/MEK和FAK抑制剂组合显示对KRAS突变型肿瘤有活性 RAF/MEK and FAK inhibitor demonstrated clinical activity in KRAS-mutated tumor
2020/7/11: 改良的蒽环类药物可保持抑制肿瘤的能力而减少心脏损害 Modified anthracycline retains ability to damage DNA while reducing cardiotoxicity
2020/4/19: 验血测试早期发现胃肠道癌症 Blood test for early detection of gastrointestinal cancers
2020/3/22: Tipifarnib可在HRAS突变型头颈部鳞状细胞癌中获得完全疾病控制 Tipifarnib had complete control of HRAS-mutant head and neck squamous cell carcinoma
2020/3/1: 新的药物组合和顺序对治疗胰腺癌有希望 New drug combination and sequencing shows promise in pancreatic cancer treatment
2020/2/8: APR-246和Azacitidine对有TP53突变的骨髓增生异常综合症的安全性和有效性 Safety and efficacy of combination therapy of APR-246 and azacytidine towards MDS with TP53 mutation
2020/1/26: 凝血蛋白和血小板可以促进免疫逃逸和癌症进展 Thrombin can promote platelet in cancer progression and evading immunotherapy
2020/1/19: 新的纳米颗粒疗法在治疗三阴性乳腺癌方面比 Protein Bound Paclitaxel（Abraxane）更有效 New nanoparticle drug more effective than standard therapy for triple-negative breast cancer
2020/1/4: 抗CD73抗体在晚期癌症治疗中的希望 Anti-CD73 antibody in advanced stage solid tumors
预防和流行病学 Prevention and epidemiology:
2020/11/15: 腰以下的诊断性放射可能会增加睾丸癌的风险 Diagnostic radiation below the waist may increase the risk of testicular cancer
2020/3/28: 乳腺癌化疗期间服用抗氧化剂和某些补品可能弊大于利 Taking antioxidants and some supplements during chemotherapy may be harmful
2020/3/21: 绝经后妇女单独使用雌激素有保护作用(?)，但雌激素加孕激素有害 Estrogen alone protective to postmenopausal women (?) while estrogen plus progesterone harmful
2020/1/18: 2020年数据报告显示最大单年度癌症死亡率下降 2020 statistic report shows largest one year drop in cancer mortality
副作用 Side-effects
2020/9/12: 最近进展–>免疫检查点抑制剂增加结核病感染的罕见风险 Check-point inhibitors may rarely increase infections of mycobacteria infections
问题解答 Q&A副作用